Cotinga Pharmaceuticalsの簿価
Cotinga Pharmaceuticalsの簿価 は何ですか。
Cotinga Pharmaceuticals, Inc.の簿価 は-0.18です。
簿価 の定義は何ですか。
1株当たりの帳簿価額は、会社の資産から会社の負債を差し引いた数を発行済株式数で割ったものです。
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
TSXVのセクタHealth Careにおける簿価 の企業と比べるCotinga Pharmaceuticals
Cotinga Pharmaceuticalsは何をしますか。
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Cotinga Pharmaceuticalsと類似の簿価
- Alpha MOS SAの簿価 は-0.18です。
- China Bozza Developmentの簿価 は-0.18です。
- ImaginOnの簿価 は-0.18です。
- Canxgold Mining Corpの簿価 は-0.18です。
- Smart Employee Benefitsの簿価 は-0.18です。
- Aton Resourcesの簿価 は-0.18です。
- Cotinga Pharmaceuticalsの簿価 は-0.18です。
- Pixium Vision SAの簿価 は-0.18です。
- Atlantic Avenue Acquisition Corpの簿価 は-0.18です。
- Navya SAの簿価 は-0.18です。
- LightJump Acquisitionの簿価 は-0.18です。
- MedMen Enterprisesの簿価 は-0.18です。
- Global Bio-chem Technologyの簿価 は-0.17です。